Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

NCT03587376 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Atabecestat

Sponsor

Janssen Research & Development, LLC